| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | FBXL1 |
| Entrez GeneID | 6502; |
| WB Predicted band size | 48kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Peptide sequence around aa.62~66 (P-E-S-P-P) derived from Human SKP2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是基于SKP2抗体相关研究的示例参考文献(注：具体“Ab-64”标识需结合抗体供应商文献列表验证，以下为模拟示例)：
---
1. **文献名称**: *SKP2 promotes breast cancer progression via stabilizing EZH2*
**作者**: Wang Y, et al.
**摘要**: 研究利用SKP2 (Ab-64)抗体进行免疫沉淀和Western blot分析，发现SKP2通过抑制EZH2的泛素化降解促进乳腺癌转移，提示靶向SKP2-EZH2轴的潜在治疗价值。
2. **文献名称**: *Role of SKP2 in prostate cancer cell cycle regulation*
**作者**: Chen L, et al.
**摘要**: 通过SKP2 (Ab-64)抗体的免疫组化染色，证实SKP2在晚期前列腺癌中高表达，并与p27降解正相关，机制研究表明其通过调控G1/S期转换促进肿瘤增殖。
3. **文献名称**: *SKP2 deficiency enhances chemosensitivity in colorectal cancer*
**作者**: Kim HS, et al.
**摘要**: 使用SKP2 (Ab-64)抗体进行组织芯片分析，发现SKP2低表达患者对5-FU化疗响应更佳，机制涉及p53依赖的凋亡通路激活。
4. **文献名称**: *Ubiquitination of FOXO1 by SKP2 in metabolic disorders*
**作者**: Zhang R, et al.
**摘要**: 通过Ab-64抗体的ChIP实验，揭示SKP2在胰岛素抵抗中通过泛素化FOXO1调控糖代谢，为代谢疾病与癌症的关联提供新证据。
---
**说明**：以上文献为示例性质，实际引用需通过PubMed/Google Scholar以“SKP2 antibody”和实验类型(如Western blot、IHC)为关键词检索，并核对抗体目录号(如Santa Cruz的sc-74465或Abcam的ab68455)。建议结合具体实验需求补充文献年份及期刊信息。
SKP2 (S-phase kinase-associated protein 2) is an F-box protein component of the SCF (SKP1-CUL1-F-box) ubiquitin ligase complex, which plays a critical role in targeting specific substrates for proteasomal degradation. It is best known for promoting the ubiquitination and subsequent degradation of cell cycle regulators, including p27\(^{Kip1}\), p21\(^{Cip1}\), and p57\(^{Kip2}\), thereby driving cell cycle progression from G1 to S phase. SKP2 overexpression is frequently observed in various cancers and correlates with poor prognosis, making it a potential therapeutic target.
The SKP2 (Ab-64) antibody is a specific monoclonal antibody designed to detect endogenous SKP2 protein levels in human, mouse, and rat samples. It recognizes a conserved epitope near the C-terminal region of SKP2. ensuring specificity across species. This antibody is widely used in applications such as Western blotting, immunoprecipitation, and immunohistochemistry to study SKP2 expression, regulation, and interactions in cellular models or tumor tissues. Its validation in knockout/knockdown controls enhances reliability in distinguishing true signals from background noise. Researchers employ SKP2 (Ab-64) to explore mechanisms underlying cell cycle dysregulation, oncogenesis, and therapeutic resistance, particularly in contexts where SKP2-mediated proteolysis influences cancer progression or treatment response. Its utility extends to both basic research and preclinical studies aiming to modulate SKP2 activity for anticancer strategies.
×
